These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

804 related articles for article (PubMed ID: 25532680)

  • 1. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
    Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
    Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
    Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
    Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients.
    Gilden DM; Kubisiak JM; Pohl GM; Ball DE; Gilden DE; John WJ; Wetmore S; Winfree KB
    J Med Econ; 2017 Feb; 20(2):151-161. PubMed ID: 27574722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?
    Sacher AG; Le LW; Lau A; Earle CC; Leighl NB
    Cancer; 2015 Aug; 121(15):2562-9. PubMed ID: 25891153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare.
    Ramsey SD; Howlader N; Etzioni RD; Donato B
    J Clin Oncol; 2004 Dec; 22(24):4971-8. PubMed ID: 15611512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Referral patterns in advanced non-small cell lung cancer: impact on delivery of treatment and survival in a contemporary population based cohort.
    Noonan K; Tong KM; Laskin J; Melosky B; Sun S; Murray N; Ho C
    Lung Cancer; 2014 Dec; 86(3):344-9. PubMed ID: 25439436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population.
    Erb CT; Su KW; Soulos PR; Tanoue LT; Gross CP
    Lung Cancer; 2016 Sep; 99():200-7. PubMed ID: 27565940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
    Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
    BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER-Medicare study.
    Shao C; He J; Kachroo S; Jin F
    Cancer Med; 2019 Dec; 8(18):7613-7622. PubMed ID: 31668011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer.
    Davidoff AJ; Gardner JF; Seal B; Edelman MJ
    J Thorac Oncol; 2011 May; 6(5):934-41. PubMed ID: 21372743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization pattern and service settings of palliative care for patients with metastatic non-small cell lung cancer.
    Huo J; Hong YR; Turner K; Bian J; Grewal R; Wilkie DJ
    Cancer; 2019 Dec; 125(24):4481-4489. PubMed ID: 31449674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic analysis of sublobar resection versus thermal ablation for early-stage non-small-cell lung cancer.
    Kwan SW; Mortell KE; Hippe DS; Brunner MC
    J Vasc Interv Radiol; 2014 Oct; 25(10):1558-64; quiz 1565. PubMed ID: 25130308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
    Meyers J; Yu Y; Kaye JA; Davis KL
    Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.
    Karve SJ; Price GL; Davis KL; Pohl GM; Smyth EN; Bowman L
    BMC Health Serv Res; 2014 Nov; 14():555. PubMed ID: 25392276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer.
    Harris JP; Patel MI; Loo BW; Wakelee HA; Diehn M
    Lung Cancer; 2017 Jun; 108():173-182. PubMed ID: 28625632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
    Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
    J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.
    Iezzoni LI; Ngo LH; Li D; Roetzheim RG; Drews RE; McCarthy EP
    Arch Phys Med Rehabil; 2008 Apr; 89(4):595-601. PubMed ID: 18373987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.